QUEBEC CITY, April 2, 2013 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR)
(OTCQX: DGCRF), today announced that the Company's stock is now trading
on OTCQXInternational under the symbol "DGCRF". OTCQX is the best U.S. OTC
marketplace, providing an opportunity to significantly broaden and
enhance DiagnoCure's access and exposure within the U.S. market. The
OTCQX marketplace has earned an exemplary reputation for providing U.S.
investors with improved liquidity, transparency, superior information,
and easy access through their U.S. regulated broker dealers. It is also
recognized within the industry for maintaining rigid quotation
standards for companies that trade there. Investors can find current
financial disclosures and Real-Time Level 2 quotes for DiagnoCure on www.otcmarkets.com.
In addition, DiagnoCure announced today that its company information
would be made available via Standard & Poor's Corporation Records
Listing Program. As part of the program, a full description of
DiagnoCure will be published in the Daily News Section of Standard &
Poors' Corporation Records, a recognized securities manual for
secondary trading in up to 38 states under the Blue Sky Laws. Standard
& Poor's Corporation Records is available in print, CD-ROM, and via the
web at www.netadvantage.standardandpoors.com as well as through numerous electronic vendors. The company information
about DiagnoCure to be made available through this program includes an
in-depth description of the DiagnoCure's business operations, share
price, dividend history, shares outstanding, company financial
position, earnings, and full income statement and balance sheet.
Canaccord Genuity will be the market maker of DiagnoCure's stock.
Canaccord Genuity is a global, full-service investment bank focused on
growth companies and is one of the largest market maker in the United
Dorsey & Whitney LLP will serve as DiagnoCure's Principal American
Liaison ("PAL") on OTCQX, responsible for providing guidance on OTCQX
requirements and U.S. securities laws.
"Trading on OTCQX International will provide enhanced access to U.S.
investors and the ability for DiagnoCure to diversify its shareholder
base," said Chantal Miklosi, Chief Financial Officer of DiagnoCure. "We
believe that trading on the OTCQX marketplace is in the best interest
of shareholders and will enable the Company to enhance the market
liquidity of DiagnoCure shares."
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that
develops and commercializes high-value cancer diagnostic tests that
increase clinician and patient confidence in making critical treatment
decisions. In 2008, the Corporation launched a colorectal cancer
staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a
worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary
of Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the
development and commercialization of a prostate cancer test using PCA3,
DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is
approved for commercialization in Canada and the United States. For
more information, visit www.diagnocure.com.
This release contains "forwardlooking statements," within the meaning
of applicable United States and Canadian securities laws, that involve
known and unknown risks, uncertainties and assumptions that may cause
actual results to differ materially from those expected. By their very
nature, forwardlooking statements are based on expectations and
hypotheses and also involve risks and uncertainties, known and unknown,
many of which are beyond DiagnoCure's control. As a result, investors
are cautioned not to place undue reliance on these forwardlooking
statements. Such forward-looking statements include the outcome of
research and development projects, clinical studies, future revenues,
the benefits of being quoted on the OTCQX and the improved liquidity of
the Company's shares when traded on the OTCQX and are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forwardlooking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE DiagnoCure inc.